We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

4 hedge funds and large institutions have $606K invested in ProShares UltraShort NASDAQ Biotechnology in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more capital invested

Capital invested by funds: $283K → $606K (+$323K)

6.9% more ownership

Funds ownership: 5.3% → 12.2% (+6.9%)

0% more funds holding

Funds holding: 4 → 4 (0)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$333K
2
TRCT
Tower Research Capital (TRC)
New York
+$14.2K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$582K +$333K +18,598 +129%
TRCT
2
Tower Research Capital (TRC)
New York
$23.4K +$14.2K +793 +149%
Morgan Stanley
3
Morgan Stanley
New York
$21 – – –
UBS Group
4
UBS Group
Switzerland
$9 – – –

BIS Hedge Fund Activity: Q1 2026 in Review

4 of the 8,132 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2026, worth a combined $606K — up 114% from $283K a quarter earlier.

Fund positioning in BIS was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $333K.

  • 4 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $606K of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2026, up 114% quarter-over-quarter.
  • 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2026 and 0 closed out.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2026 was Susquehanna International Group, an estimated $333K added.

Based on aggregated 13F filings for Q1 2026.